Bristol Myers Revise 2023 Outlook After Revenue Decline

Bristol Myers Revise 2023 Outlook After Revenue Decline

Last year, Bristol Myers Squibb achieved a significant milestone by securing FDA approvals for three drugs, each with a peak…

Read More »